Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Sep 24:42:49-51.
doi: 10.1016/j.jdcr.2023.08.048. eCollection 2023 Dec.

A case of leukocytoclastic vasculitis in a patient on dupilumab

Michelle S Bach  1 , Brett H Keeling  2 , Elizabeth Yim  2
Affiliations
Case Reports

A case of leukocytoclastic vasculitis in a patient on dupilumab

Michelle S Bach et al. JAAD Case Rep. .
No abstract available

Keywords: adverse reaction; biologic treatment for atopic dermatitis; dupilumab; leukocytoclastic vasculitis.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Clinical presentation. Palpable nonblanching purpura of the lower extremities.
Fig 2
Fig 2
Histopathological examination of the left lower extremity demonstrates abundant extravasation of erythrocytes in surrounding vessels within the dermis, extensive infiltration of vessel walls by mixed inflammation, including lymphocytes, histiocytes, neutrophils, and multiple eosinophils, and nuclear dust consistent with karyorrhexis (A and B). Minimal fibrinoid change was seen within occasional inflamed superficial dermal vessel walls. All features were consistent with leukocytoclastic vasculitis (Hematoxylin-eosin stain; 10×, and 20× respectively).
See this image and copyright information in PMC

References

    1. Thibodeaux Q., Smith M.P., Ly K., Beck K., Liao W., Bhutani T. A review of dupilumab in the treatment of atopic diseases. Hum Vacc Immunother. 2019;15(9):2129–2139. doi: 10.1080/21645515.2019.1582403. - DOI - PMC - PubMed
    1. Mustin D.E., Cole E.F., Blalock T.W., Kuruvilla M.E., Stoff B.K., Feldman R.J. Dupilumab-induced erythema nodosum. Jaad Case Rep. 2022;19:41–43. doi: 10.1016/j.jdcr.2021.11.007. - DOI - PMC - PubMed
    1. Albader S.S., Alharbi A.A., Alenezi R.F., Alsaif F.M. Dupilumab side effect in a patient with atopic dermatitis: a case report study. Biologics Targets Ther. 2019;13:79–82. doi: 10.2147/btt.s195512. - DOI - PMC - PubMed
    1. Hammadi A.A., Parmar N.V. Erythema, pruritus, and diffuse peeling of skin during dupilumab therapy for atopic dermatitis in three adults. Int J Dermatol. 2019;58(1):e14–e15. doi: 10.1111/ijd.14296. - DOI - PubMed
    1. Grinich E.E., Simpson E.L. Comprehensive Dermatologic Drug Therapy. Elsevier; 2020. Additional biologic therapeutics: dupilumab, omalizumab, others.

Publication types

LinkOut - more resources